Clinical Trials List
2021-11-15 - 2024-03-15
Phase I
Terminated3
ICD-10D02.20
Carcinoma in situ of unspecified bronchus and lung
ICD-10D02.21
Carcinoma in situ of right bronchus and lung
ICD-10D02.22
Carcinoma in situ of left bronchus and lung
ICD-9231.2
Carcinoma in situ of bronchus and lung
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Cheng-Ta Yang Division of Thoracic Medicine
- Ping-Chih Hsu Division of Thoracic Medicine
- 吳教恩 Division of Hematology & Oncology
- Chih-Hung Chen Division of Thoracic Medicine
- Shih-Hong Li Division of Thoracic Medicine
- 張境夫 Division of Hematology & Oncology
- Chih-Liang Wang Division of Thoracic Medicine
- 吳振德 Division of Radiology
- Chih-Hsi Kuo Division of Thoracic Medicine
- 枋岳甫 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 黃子權 Division of Hematology & Oncology
- 賴學緯 Division of Hematology & Oncology
- 陳宇欽 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
- 何景良 Division of Hematology & Oncology
- 吳宜穎 Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- 陳佳宏 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 李玫萱 Division of Thoracic Medicine
- Inn-Wen Chong Division of Thoracic Medicine
- 郭家佑 Division of Thoracic Medicine
- Chih-Jen Yang Division of Thoracic Medicine
- KUAN-LI WU Division of Thoracic Medicine
- Ying-Ming Tsai Tsai Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
332 participants
